Optimizing bactericidal exposure for beta-lactams using prolonged and continuous infusions in the pediatric...

Area of Science:

• Pediatric pharmacology
• Infectious diseases
• Pharmacokinetics and pharmacodynamics

Background:

• Beta-lactam antibiotics are crucial for treating pediatric infections.
• Children's higher drug clearance necessitates optimized dosing strategies.
• Prolonged or continuous infusion of beta-lactams is effective in adults.

Purpose of the Study:

• To evaluate the efficacy of prolonged and continuous infusion strategies for beta-lactams in pediatric populations.
• To determine optimal dosing regimens for commonly used beta-lactams in children.
• To assess the probability of target attainment (PTA) and cumulative fractions of response (CFR) for various infusion durations.

Main Methods:

• Simulated Monte Carlo analysis of cefepime, ceftazidime, imipenem/cilastatin, meropenem, and piperacillin/tazobactam.
• Evaluated 0.5-hour, 3-hour, and 24-hour infusion regimens in simulated 2- and 12-year-old pediatric populations.
• Utilized MIC data for Pseudomonas aeruginosa from two pediatric acute care institutions to calculate CFR.

Main Results:

• Standard 0.5-hour infusions showed poor PTA for most beta-lactams at their susceptibility breakpoint.
• 3-hour infusions significantly improved PTA for cefepime, ceftazidime, imipenem, and meropenem.
• Continuous infusions yielded similar PTA to 3-hour infusions, and both improved CFR compared to shorter infusions.

Conclusions:

• Prolonged (3-hour) and continuous infusion strategies enhance the likelihood of achieving bactericidal targets for beta-lactams in pediatric patients.
• These findings support the need for clinical trials to investigate these optimized beta-lactam dosing strategies in children.
• Optimized infusion strategies may improve treatment outcomes for pediatric infections caused by susceptible pathogens.